bibliographicCitation |
Jiang W, Guan R, Shao YW, Wang B, Wang Y. Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib. JTO Clinical and Research Reports. 2020 Jun;1(2):100009. doi: 10.1016/j.jtocrr.2020.100009. |